Ysios CapitalFundingYsios Capital launches InceptionBio: €100m for Spanish biotech spinoutsSpanish VC firm Ysios Capital has unveiled InceptionBio, a €100 million fund dedicated to boosting Spanish biotech innovation. The initiative targets company creation from top-tier research, backed … more ➔
123rf.com/Paul GrecaudFinancingEIF starts €15bn fund-of-funds for scaling European tech companiesThe European Investment Fund has launched a new fund of funds with a target volume of €15 billion to strengthen growth financing in Europe’s technology sector. The programme is considered the largest … more ➔
Unsplash+FundraisingTenBoron lands €7.6m EU grant for precision radiotherapy trials in hard-to-treat cancersFinnish clinical stage biotech TenBoron Oy has landed a €7.6m grant from the European Union’s Horizon Europe Health 2025 programme. The funding will propel its boron carrier platform for a novel … more ➔
Unsplash+FinancingImmutrin secures £65m Series A for amyloid-removing heart therapyImmutrin, a UK biotech, has raised £65m (€75m) in Series A funding for a pioneering antibody designed to remove pre-existing amyloid deposits in amyloidosis. more ➔
RocheOrganoids and Lab-on-chipOrganoids: new Roche research centre in Basel will focus on alternative model systemsAnimal testing or organoids—this question is increasingly being answered in favour of organoids. Yet robust model systems still require further research and, crucially, validation. More large pharmaceutical … more ➔
Picture by Joanna Kosinska via UnsplashLicencingSanofi inks up-to-$1.2bn autoimmune T-cell engager deal with Kali TherapeuticsSanofi is expanding its immunology toolbox: The French pharma pays up to US$1.2bn for worldwide exclusive rights to Kali Therapeutics’ next-generation tri-specific T-cell engager targeting B cell-mediated … more ➔
Unsplash+FinancingDutch biotech Laigo Bio bags €17m in oversubscribed seed roundMembrane protein degradation specialist Laigo Bio has completed the final close of its €17m (US$18.5m) seed financing. Funds will go towards the oncology and auto-immunity programmes based on the company’s … more ➔
adobe stock photos - Michael Derrer Fuchs SwitzerlandNovartis strikes another billion-dollar oncology deal with acquisition of an early PI3Kalpha oral therapyNovartis is pressing ahead with its aggressive expansion strategy in oncology, striking again: the Basel-based group is acquiring a novel PI3Kalpha inhibitor from Synnovation Therapeutics for up to USD … more ➔
adobe stock photos - Sundry Photography RocheSwiss Roche builds its own AI factory with NVIDIA – with Genentech in CaliforniaThe Basel-based pharmaceutical group Roche is pressing ahead with its digital strategy and setting new benchmarks for the industry. Together with NVIDIA, the company is building an “AI factory” that … more ➔
FundraisingMestag Therapeutics raises $40M and adds two senior biotech executives as lead cancer program nears the clinicUK biotech Mestag Therapeutics has raised $40 million and appointed veteran drug developers Lindsey Rolfe as chief medical officer and Pascal Merchiers as chief development officer, as the company prepares … more ➔
Ysios Capital
123rf.com/Paul Grecaud
Unsplash+
Unsplash+
Roche
Picture by Joanna Kosinska via Unsplash
Unsplash+
adobe stock photos - Michael Derrer Fuchs 
adobe stock photos - Sundry Photography 
